Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
CELLINK’s goal is to grow sales organically with a minimum of 35% per year and grow additionally through acquisitions.
Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.
UK Innovation & Science Seed Fund, Catapult Ventures’ GM&C Life Sciences Fund and Jonathan Milner are pleased to announced an investment in Pencil Biosciences, a novel gene modulation company based at Alderley Park, Cheshire.
The Beacon optofluidic technology will be used to speed the identification of lifesaving treatments for deadly viruses including Ebola, Lassa and others.
AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB.
StartX Med company Kodiak Sciences, a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases, recently reached a market cap of $3.56 billion.
Recipharm, the contract development and manufacturing organisation, has invested USD 450,000 into its Research Triangle Park, North Carolina, US facility to install a SprayVIEW® system that will support inhalation and nasal product development.
Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
Ardelyx, Inc. has announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000.